"It has developed several types of resistance to vancomycin, a glycopeptide, which for decades was the MRSA drug of last resort, and is beginning to exhibit resistance to drugs in newly developed families that were intended to replace vancomycin: linezolid (Zyvox), an oxazolidinone, and daptomycin (marketed as Cubicin), a lipopeptide."